Pfizer to Acquire Immuneering for $625M
Ticker: IMRX · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, pharma
TL;DR
Pfizer buying Immuneering for $625M cash ($60/share), deal expected Q3 2025.
AI Summary
Immuneering Corp. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is valued at approximately $625 million, with Pfizer paying $60.00 per share in cash for all outstanding shares of Immuneering. The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Pfizer could accelerate the development of Immuneering's promising drug candidates, potentially bringing new treatments to patients faster.
Risk Assessment
Risk Level: medium — The deal is subject to customary closing conditions, and regulatory approval could pose a risk to the completion of the acquisition.
Key Numbers
- $625M — Acquisition Value (Total cash consideration for Immuneering Corp.)
- $60.00 — Price Per Share (Cash amount Pfizer will pay for each Immuneering share.)
Key Players & Entities
- Immuneering Corp. (company) — Company being acquired
- Pfizer Inc. (company) — Acquiring company
- $625 million (dollar_amount) — Total acquisition value
- $60.00 (dollar_amount) — Price per share
- June 17, 2025 (date) — Date of announcement
- third quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement between Pfizer and Immuneering?
The definitive agreement values Immuneering Corp. at approximately $625 million.
What price per share will Pfizer pay for Immuneering's stock?
Pfizer will pay $60.00 per share in cash for all outstanding shares of Immuneering.
When is the acquisition expected to be completed?
The transaction is expected to close in the third quarter of 2025.
What is the filing date of this 8-K report?
The report was filed on June 17, 2025.
What is the primary business of Immuneering Corp.?
Immuneering Corp. is involved in pharmaceutical preparations, as indicated by its SIC code [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Immuneering Corp (IMRX).